Background Cancer immunotherapy has revolutionized cancer treatment. However,
considering the limited success of immunotherapy to only some cancer types and patient …

Despite major progress in the treatment of rheumatoid arthritis (RA), strong unmet medical
need remains, as only a minor proportion of patients reach sustained clinical remission. New …

Inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel
diseases, multiple sclerosis, psoriasis and asthma, provide drug discoverers with a …

Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis
factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With …

Inflammation may be defined as the normal response of living tissue to injury or infection. It
is important to emphasize two components of this definition. First, that inflammation is a …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Interleukin-2 (IL-2) is integral to immune system regulation. Its opposing immunostimulatory
and immunosuppressive actions make it an attractive therapeutic target for cancer and …

Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several
autoimmune disorders. Several of these cytokines are directly implicated in the …

Therapeutically controlling inflammation is essential for the clinical management of many
high-prevalence human diseases. Drugs that block the pro-inflammatory cytokines tumour …

Autoimmune diseases affect about 3% of the world population, more frequently women than
men, and their incidence is attributed to an immune response of a genetically predisposed …